On July 1, 2026, Tennessee's ban on kratom took effect. After twelve years in this industry, I've watched enough of these debates to know that how a state writes a law matters as much as whether it acts at all, and Tennessee's approach is worth examining closely, because it reflects a choice that other states are still weighing.
What Tennessee Actually Passed
The law is HB1649, signed by Governor Bill Lee on May 7, 2026 as Public Chapter 950 and known as "Matthew Davenport's Law." It is named for a Chattanooga man who died in 2024 after an adverse interaction between kratom and his prescription medications. Under the new statute, kratom is banned in all forms, natural leaf and concentrated products alike, and possession is a Class A misdemeanor.
I want to be clear about something up front: the family behind this law lost someone, and the concern that drove it, how botanicals interact with prescription medications, is a legitimate one that our industry should take seriously, not dismiss. Where I part ways is on the remedy. As the Nashville Banner reported, the bill's sponsor described kratom, in both its natural and processed forms, in the same breath. That framing collapsed a distinction that good policy depends on.
Alt text: "Tennessee State Capitol building in Nashville, representing 2026 state kratom legislation."
Prohibition Was Not the Only Option on the Table
This is the part of the story that rarely gets told. Tennessee lawmakers also considered a regulatory alternative, HB2594, that would have set standards and limits rather than imposing a blanket ban. That bill did not advance. Legislators chose prohibition over regulation, not because regulation was unavailable, but because it was set aside.
Other states have taken the opposite road. Consumer-protection frameworks now on the books elsewhere require age restrictions, ingredient labeling, and prohibitions on adulterated or chemically altered products. Those laws target the actual sources of risk while keeping a tested, transparent, adult market intact. That is the difference between governing a product and outlawing it.
The Distinction the Ban Blurred: Leaf vs. Concentrate
The most important line in this entire debate is the one between natural kratom leaf and highly concentrated or semi-synthetic derivatives. They are not the same category, and regulators increasingly treat them differently. In 2025, the FDA formally recommended that the DEA schedule concentrated 7-hydroxymitragynine (7-OH) products, a specific class of potent, processed compounds, while conventional leaf kratom was handled separately.
That is a meaningful distinction, and it's one we spend a lot of time explaining to our own customers. Understanding the difference between natural kratom powder and concentrated extracts is exactly the kind of consumer education that a regulatory framework can encourage and a total ban erases. When a law treats every form identically, it loses the ability to address the products that actually warrant closer scrutiny.
Alt text: "Natural Mitragyna speciosa kratom leaves shown alongside a concentrated extract, illustrating two distinct product categories."
What the Research Says About Blanket Scheduling
The policy questions here aren't new, and they've been studied. A peer-reviewed eight-factor analysis of kratom's abuse potential, led by Dr. Jack Henningfield and colleagues at PinneyAssociates and first published in 2018 (with a 2021 update reviewing more than 100 subsequent studies), examined kratom against the same criteria the Controlled Substances Act uses for scheduling decisions.
Research from that body of work suggests that the abuse potential of mitragynine, kratom's primary alkaloid, falls within the range of many substances that remain uncontrolled, and the authors argued that Schedule I listing would carry its own public-health costs, including criminalizing consumers and impeding research. Their recommendation was not "do nothing." It was regulation aimed at contaminated, adulterated, and inappropriately marketed products: precisely the middle path Tennessee declined to take.
I'll add my own view here, since this is an opinion piece and my name is on it: when demand for a product is well established, removing the legal, tested supply doesn't remove the demand. It relocates it. A regulated shelf with lab reports and age checks is a safer place for an adult to make a decision than an unregulated one.
Where Real Consumer Protection Actually Lives
If the goal is genuinely public safety, the tools already exist, and responsible vendors already use them. At NuWave Botanicals, our standards center on verified third-party lab testing and batch-specific Certificates of Analysis, manufacturing in American Kratom Association GMP-qualified facilities, clear labeling, and strict age verification. Every batch across our lab-tested kratom catalog is documented and traceable.
None of that is possible in a prohibited market. Bans don't produce Certificates of Analysis; they produce a vacuum that testing, labeling, and accountability standards can no longer reach. The irony of prohibition is that it removes the very transparency infrastructure that protects consumers.
A Better Path Forward
We would rather be held to a rigorous standard than be legislated out of existence, and that's not a contradiction; it's the entire point. Science-based regulation asks vendors to prove quality, verify age, and keep dangerous adulterants off the shelf. Prohibition asks nothing of anyone and simply moves the market somewhere no one is watching.
Tennessee had a regulatory bill in front of it and chose a ban instead. As other states take up the same question, the distinction between those two paths is the one that deserves the debate. We'll continue to advocate for the approach that keeps adults informed, products tested, and the actual risks in view.
Alt text: "Third-party laboratory Certificate of Analysis for a kratom batch, illustrating the transparency standards prohibition removes."
NuWave Botanicals products are intended strictly for adults 18 years of age or older, or 21+ where applicable by local law. These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure, or prevent any disease. This article is commentary on public policy and is not legal advice. Questions? Contact us at orders@nuwavebotanicals.com.